Table 3. . Pooled treatment-emergent adverse events in Phase III sarecycline studies.
TEAE safety population (≥2% in either group) | SC1401 and SC1402 pooled, n (%) | |
---|---|---|
Sarecycline (n = 994) | Placebo (n = 996) | |
Nasopharyngitis | 28 (2.8) | 23 (2.3) |
Upper respiratory infection | 16 (1.6) | 16 (1.6) |
Headache | 28 (2.8) | 38 (3.8) |
Nausea | 32 (3.2) | 17 (1.7) |
Vomiting | 13 (1.3) | 9 (0.9) |
Urinary tract infection | 3 (0.3) | 11 (1.1) |
TEAE: Treatment-emergent adverse events.
Data taken from [25].